1MARTIN M G,ABBOUD C N.Induction therapy for elderly patients with acute myeloid leukemia[J].Blood Rev,2008,22:311-320.
2SOLARY E,CASASNOVAS R O,CAMPOS L,et al.Surface markers in adult acute myeloblastic leukemia:correlation of CD191,CD341 and CD141/DR2 phenotypes with shorter survival.Groupe d'Etude Immunologique des Leucemies (GEIL)[J].Leukemia,1992,6:393-399.
3PLESA C,CHELGHOUM Y,PLESA A,et al.Prognostic value of immunophenotyping in elderly patients with acute myeloid leukemia cancer[J].Cancer,2008,112:572-580.
4APPELBAUM F R,GUNDACKER H,HEAD D R,et al.Age and acute myeloid leukemia[J].Blood,2006,107:3481-3485.
5LOWENBERG B,ZITTOUN R,KERKHOFS H,et al.On the value of intensive remission-induction chemotherapy in elderly patients of 65+ years with acute myeloid leukemia:a randomized phase III study of the European organization for the research and treatment of cancer leukemia group[J].J Clin Oncol,1989,7:1268-1274.
6TILLY H,CASTAIGNE S,BORDESSOULE D,et al.Low-dose cytarabine versus intensive chemotherapy in the treatment of acute nonlymphocytic leukemia in the elderly[J].J Clin Oncol,1990,8:272-279.
7BURNETT A K,MILLIGAN D,PRENTICE A G,et al.A comparison of low-dose cytarabine and hydroxyurea with or without alltrans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment[J].Cancer,2007,109:1114-1124.
